Abstract
Yaroslava V. Chervyakova, Alena V. Smirnova, Andrei E. Siniavin, Vasilisa E. Soldatova, Diana D. Gamzik, Anna V. Tvorogova, Islam Nakastoev, Alexander V. Filatov, Natalia A. Kruglova, Alexandra Maslennikova
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
10.3389/fcimb.2022.880030
10.3389/fcimb.2022.880030
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
10.1056/nejmoa0802905 · 2009
Evidence for the Cure of HIV Infection by CCR5Δ32/Δ32 Stem Cell Transplantation
10.1182/blood-2010-09-309591 · 2011
10.1371/journal.ppat.1003347
10.1371/journal.ppat.1003347
HIV-1 Remission Following CCR5Δ32/Δ32 Haematopoietic Stem-Cell Transplantation
10.1038/s41586-019-1027-4 · 2019
Evidence for HIV-1 Cure after CCR5Δ32/Δ32 Allogeneic Haemopoietic Stem-Cell Transplantation 30 Months Post Analytical Treatment Interruption: A Case Report
10.1016/s2352-3018(20)30069-2 · 2020
MRNA Transfection of a Novel TAL Effector Nuclease (TALEN) Facilitates Efficient Knockout of HIV Co-Receptor CCR5
10.1093/nar/gkv469 · 2015
Shift of HIV Tropism in Stem-Cell Transplantation with CCR5 Delta32 Mutation
10.1056/nejmc1405805 · 2014
Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection
10.1089/hum.2017.032 · 2017
Genome Editing of the HIV Co-Receptors CCR5 and CXCR4 by CRISPR-Cas9 Protects CD4+ T Cells from HIV-1 Infection
10.1186/s13578-017-0174-2 · 2017
Mutual, Reciprocal SDF-1/CXCR4 Interactions between Hematopoietic and Bone Marrow Stromal Cells Regulate Human Stem Cell Migration and Development in NOD/SCID Chimeric Mice
10.1016/j.exphem.2006.04.002 · 2006
CXCR4 Is Required for the Quiescence of Primitive Hematopoietic Cells
10.1084/jem.20072513 · 2008
Generation of Human TRIM5α Mutants with High HIV-1 Restriction Activity
10.1038/gt.2010.40 · 2010
Human Immunodeficiency Virus Type 1 Restriction by Human–Rhesus Chimeric Tripartite Motif 5α (TRIM 5α) in CD34+ Cell-Derived Macrophages In Vitro and in T Cells In Vivo in Severe Combined Immunodeficient (SCID-Hu) Mice Transplanted with Human Fetal Tissue
10.1089/hum.2007.108 · 2008
Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene
10.1089/hum.2015.059 · 2015
Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma
10.1016/j.omtm.2019.02.006 · 2019
Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector
10.1038/mtna.2015.10 · 2015
Multilineage Polyclonal Engraftment of Cal-1 Gene-Modified Cells and in Vivo Selection after SHIV Infection in a Nonhuman Primate Model of AIDS
10.1038/mtm.2016.7 · 2016
Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of Gp41
10.1128/mbio.03589-21 · 2022
10.3390/v11080705
10.3390/v11080705
A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
10.1128/jvi.01839-16 · 2017
A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
10.1128/jvi.01177-19 · 2019
Unraveling Viral Drug Targets: A Deep Learning-Based Approach for the Identification of Potential Binding Sites
10.1093/bib/bbad459 · 2023
Monoclonal Antibody Profiling of Cell Surface Proteins Associated with the Viral Biofilms on HTLV-1 Transformed Cells
10.4149/av_2015_03_247 · 2015
10.1371/journal.ppat.1000788
10.1371/journal.ppat.1000788
10.3390/v14010152
10.3390/v14010152
Improvement of HIV-1 and Human T Cell Lymphotropic Virus Type 1 Replication-Dependent Vectors via Optimization of Reporter Gene Reconstitution and Modification with Intronic Short Hairpin RNA
10.1128/jvi.01940-15 · 2015
Modulation of Human Immunodeficiency Virus Type 1 Infectivity through Incorporation of Tetraspanin Proteins
10.1128/jvi.01044-07 · 2008
Clinical Use of Lentiviral Vectors
10.1038/s41375-018-0106-0 · 2018
10.1371/journal.pone.0010611
10.1371/journal.pone.0010611
10.1371/journal.pone.0018556
10.1371/journal.pone.0018556
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
10.1006/meth.2001.1262 · 2001
A Distinct Hematopoietic Stem Cell Population for Rapid Multilineage Engraftment in Nonhuman Primates
10.1126/scitranslmed.aan1145 · 2017
Purification of Human CD34+CD90+ HSCs Reduces Target Cell Population and Improves Lentiviral Transduction for Gene Therapy
10.1016/j.omtm.2020.07.010 · 2020
Molecular Regulators of Chemotaxis in Human Hematopoietic Stem Cells
10.1042/bst20240288 · 2024
Mobilization-Based Chemotherapy-Free Engraftment of Gene-Edited Human Hematopoietic Stem Cells
10.1016/j.cell.2022.04.039 · 2022
10.3389/fimmu.2021.783022
10.3389/fimmu.2021.783022
10.1371/journal.ppat.1005983
10.1371/journal.ppat.1005983
Expression of CD4 by Human Hematopoietic Progenitors [See Comments]
10.1182/blood.v84.10.3344.3344 · 1994
Tailoring CAR Surface Density and Dynamics to Improve CAR-T Cell Therapy
10.1136/jitc-2024-010702 · 2025
10.3390/ijms21031170
10.3390/ijms21031170 · doi-reference
Chromothriptic Cure of WHIM Syndrome
10.1016/j.cell.2015.01.014 · doi-reference
Chemokine Receptor Distribution on the Surface of Repolarizing T Cells
10.1016/j.bpj.2024.02.001 · doi-reference
10.3390/ijms20010003
10.3390/ijms20010003 · doi-reference
Tailoring CAR Surface Density and Dynamics to Improve CAR-T Cell Therapy
10.1136/jitc-2024-010702 · doi-reference
Expression of CD4 by Human Hematopoietic Progenitors [See Comments]
10.1182/blood.v84.10.3344.3344 · doi-reference
10.1371/journal.ppat.1005983
10.1371/journal.ppat.1005983 · doi-reference
10.3389/fimmu.2021.783022
10.3389/fimmu.2021.783022 · doi-reference
Mobilization-Based Chemotherapy-Free Engraftment of Gene-Edited Human Hematopoietic Stem Cells
10.1016/j.cell.2022.04.039 · doi-reference
Molecular Regulators of Chemotaxis in Human Hematopoietic Stem Cells
10.1042/bst20240288 · doi-reference
Purification of Human CD34+CD90+ HSCs Reduces Target Cell Population and Improves Lentiviral Transduction for Gene Therapy
10.1016/j.omtm.2020.07.010 · doi-reference
A Distinct Hematopoietic Stem Cell Population for Rapid Multilineage Engraftment in Nonhuman Primates
10.1126/scitranslmed.aan1145 · doi-reference
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
10.1006/meth.2001.1262 · doi-reference
10.1371/journal.pone.0018556
10.1371/journal.pone.0018556 · doi-reference
10.1371/journal.pone.0010611
10.1371/journal.pone.0010611 · doi-reference
Clinical Use of Lentiviral Vectors
10.1038/s41375-018-0106-0 · doi-reference
Modulation of Human Immunodeficiency Virus Type 1 Infectivity through Incorporation of Tetraspanin Proteins
10.1128/jvi.01044-07 · doi-reference
Improvement of HIV-1 and Human T Cell Lymphotropic Virus Type 1 Replication-Dependent Vectors via Optimization of Reporter Gene Reconstitution and Modification with Intronic Short Hairpin RNA
10.1128/jvi.01940-15 · doi-reference
10.1371/journal.ppat.1000788
10.1371/journal.ppat.1000788 · doi-reference
Monoclonal Antibody Profiling of Cell Surface Proteins Associated with the Viral Biofilms on HTLV-1 Transformed Cells
10.4149/av_2015_03_247 · doi-reference
Unraveling Viral Drug Targets: A Deep Learning-Based Approach for the Identification of Potential Binding Sites
10.1093/bib/bbad459 · doi-reference
A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
10.1128/jvi.01177-19 · doi-reference
A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus
10.1128/jvi.01839-16 · doi-reference
10.3390/v11080705
10.3390/v11080705 · doi-reference
Engineering T-Cell Resistance to HIV-1 Infection via Knock-In of Peptides from the Heptad Repeat 2 Domain of Gp41
10.1128/mbio.03589-21 · doi-reference
Multilineage Polyclonal Engraftment of Cal-1 Gene-Modified Cells and in Vivo Selection after SHIV Infection in a Nonhuman Primate Model of AIDS
10.1038/mtm.2016.7 · doi-reference
Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector
10.1038/mtna.2015.10 · doi-reference
Safety of CD34+ Hematopoietic Stem Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46 in HIV-1 Infected Patients with High-Risk Lymphoma
10.1016/j.omtm.2019.02.006 · doi-reference
Preclinical Assessment of Mutant Human TRIM5α as an Anti-HIV-1 Transgene
10.1089/hum.2015.059 · doi-reference
Human Immunodeficiency Virus Type 1 Restriction by Human–Rhesus Chimeric Tripartite Motif 5α (TRIM 5α) in CD34+ Cell-Derived Macrophages In Vitro and in T Cells In Vivo in Severe Combined Immunodeficient (SCID-Hu) Mice Transplanted with Human Fetal Tissue
10.1089/hum.2007.108 · doi-reference
Generation of Human TRIM5α Mutants with High HIV-1 Restriction Activity
10.1038/gt.2010.40 · doi-reference
CXCR4 Is Required for the Quiescence of Primitive Hematopoietic Cells
10.1084/jem.20072513 · doi-reference
Mutual, Reciprocal SDF-1/CXCR4 Interactions between Hematopoietic and Bone Marrow Stromal Cells Regulate Human Stem Cell Migration and Development in NOD/SCID Chimeric Mice
10.1016/j.exphem.2006.04.002 · doi-reference
Genome Editing of the HIV Co-Receptors CCR5 and CXCR4 by CRISPR-Cas9 Protects CD4+ T Cells from HIV-1 Infection
10.1186/s13578-017-0174-2 · doi-reference
Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection
10.1089/hum.2017.032 · doi-reference
Shift of HIV Tropism in Stem-Cell Transplantation with CCR5 Delta32 Mutation
10.1056/nejmc1405805 · doi-reference
MRNA Transfection of a Novel TAL Effector Nuclease (TALEN) Facilitates Efficient Knockout of HIV Co-Receptor CCR5
10.1093/nar/gkv469 · doi-reference
Evidence for HIV-1 Cure after CCR5Δ32/Δ32 Allogeneic Haemopoietic Stem-Cell Transplantation 30 Months Post Analytical Treatment Interruption: A Case Report
10.1016/s2352-3018(20)30069-2 · doi-reference
HIV-1 Remission Following CCR5Δ32/Δ32 Haematopoietic Stem-Cell Transplantation
10.1038/s41586-019-1027-4 · doi-reference
10.1371/journal.ppat.1003347
10.1371/journal.ppat.1003347 · doi-reference